Y Liu1, X Yun, M Gao, Y Yu, X Li. 1. Department of Head and Neck Tumor, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Huanhuxi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.
Abstract
PURPOSE: Regulatory T cells (Treg) suppress the immune reaction. The aim of the present study was to investigate the clinicopathologic significance and roles of Treg in papillary thyroid carcinoma (PTC) patients with and without Hashimoto's thyroiditis. METHODS: Flow cytometry was used to detect the percentage of CD4+CD25+CD127low/- Treg among CD4+ T cells in peripheral blood. FoxP3+ Treg were detected by immunohistochemistry in the tumor tissues. RESULTS: The percentage of CD4+CD25+CD127low/- Treg among CD4+ T cells was significantly higher in PTC patients than that in multinodular goiter (MNG) patients. There were large numbers of tumor-infiltrating FoxP3+ Treg in primary PTC and metastatic lymph nodes tissues; however, there was no FoxP3 expression in the MNG tissues. Higher percentage of Treg both in peripheral blood and tumor tissues was associated with extrathyroidal extension and lymph nodes metastasis. The percentage of CD4+CD25+CD127low/- Treg among CD4+ T cells in peripheral blood of PTC patients with Hashimoto's thyroiditis (HT) was significantly lower, whereas the infiltration of FoxP3+ Treg in tissues of PTC with HT tended to be increased. CONCLUSIONS: We concluded that the percentage of Treg increased in peripheral blood as well as in the tumor tissues of PTC patients compared with that of MNG patients. The high percentage of Treg was associated with aggressiveness. There may be a compensatory expansion of Treg at the sites of inflammation in tissues of PTC with HT contributing to the immune response suppression.
PURPOSE: Regulatory T cells (Treg) suppress the immune reaction. The aim of the present study was to investigate the clinicopathologic significance and roles of Treg in papillary thyroid carcinoma (PTC) patients with and without Hashimoto's thyroiditis. METHODS: Flow cytometry was used to detect the percentage of CD4+CD25+CD127low/- Treg among CD4+ T cells in peripheral blood. FoxP3+ Treg were detected by immunohistochemistry in the tumor tissues. RESULTS: The percentage of CD4+CD25+CD127low/- Treg among CD4+ T cells was significantly higher in PTC patients than that in multinodular goiter (MNG) patients. There were large numbers of tumor-infiltrating FoxP3+ Treg in primary PTC and metastatic lymph nodes tissues; however, there was no FoxP3 expression in the MNG tissues. Higher percentage of Treg both in peripheral blood and tumor tissues was associated with extrathyroidal extension and lymph nodes metastasis. The percentage of CD4+CD25+CD127low/- Treg among CD4+ T cells in peripheral blood of PTC patients with Hashimoto's thyroiditis (HT) was significantly lower, whereas the infiltration of FoxP3+ Treg in tissues of PTC with HT tended to be increased. CONCLUSIONS: We concluded that the percentage of Treg increased in peripheral blood as well as in the tumor tissues of PTC patients compared with that of MNG patients. The high percentage of Treg was associated with aggressiveness. There may be a compensatory expansion of Treg at the sites of inflammation in tissues of PTC with HT contributing to the immune response suppression.
Authors: Hideaki Sugiyama; Rolland Gyulai; Eiko Toichi; Edina Garaczi; Shinji Shimada; Seth R Stevens; Thomas S McCormick; Kevin D Cooper Journal: J Immunol Date: 2005-01-01 Impact factor: 5.422
Authors: K Kashima; S Yokoyama; S Noguchi; N Murakami; H Yamashita; S Watanabe; S Uchino; M Toda; A Sasaki; T Daa; I Nakayama Journal: Thyroid Date: 1998-03 Impact factor: 6.568
Authors: David Anz; Stephan Eiber; Christoph Scholz; Stefan Endres; Thomas Kirchner; Carole Bourquin; Doris Mayr Journal: Histopathology Date: 2011-11 Impact factor: 5.087
Authors: Katrin Rabold; Paul R Gielen; Esther D Kers-Rebel; Mihai G Netea; Jan W A Smit; Gosse J Adema; Romana T Netea-Maier Journal: Oncologist Date: 2019-01-03
Authors: Rob J W Arts; Theo S Plantinga; Sander Tuit; Thomas Ulas; Bas Heinhuis; Marika Tesselaar; Yvette Sloot; Gosse J Adema; Leo A B Joosten; Johannes W A Smit; Mihai G Netea; Joachim L Schultze; Romana T Netea-Maier Journal: Oncoimmunology Date: 2016-09-09 Impact factor: 8.110